目的 观察重组人生长激素(rhGH)对幼年扩张型心肌病(DCM)模型大鼠左心室形态及功能的影响, 以及其对DCM的改善效果及安全性。方法 将60只Sprague-Dawley雄性大鼠随机分为空白对照组、DCM组和生长激素治疗组(rhGH组), 每组20只。呋喃唑酮(0.25 mg/g)灌胃12周制作DCM模型; rhGH组大鼠给予rhGH腹腔注射(0.15 u/kg), 每日1次, 共12周, DCM组行等量生理盐水替代腹腔注射; 空白对照组不采取任何措施。多普勒超声心动图检测心脏指数, ELISA法检测血清生化指标水平, 多导生理仪检测血流动力学指标, 普通光镜和电镜下观察各组大鼠心脏病理组织学改变, 苦味酸-天狼猩红偏振光法染色检测心肌胶原蛋白水平。结果 与对照组相比, DCM组大鼠均表现出明显心腔扩大, 室壁厚度明显变薄, 缩短分数(FS)和射血分数(EF)下降(P<0.05); rhGH组大鼠心腔容积、室壁厚度、FS和EF等均较DCM组明显改善(P<0.05), 接近对照组水平(P>0.05)。DCM组大鼠各血清生化指标和血流动力学指标水平与对照组相比差异均有统计学意义(P<0.05); 与DCM组相比, 上述指标在rhGH组均得到较大改善(P<0.05), 除胰岛素样生长因子-1(IGF-1)和IGF结合蛋白-3(IGFBP-3)外, 其余指标与对照组相比差异均无统计学意义(P>0.05)。DCM组心肌胶原蛋白ColⅠ/ColⅢ比值高于对照组和rhGH组(P<0.05), 而在对照组和rhGH组间ColⅠ/ColⅢ比值差异无统计学意义(P>0.05)。结论 rhGH对幼年DCM模型大鼠左心室形态及心功能改善具有一定的作用。
Abstract
Objective To investigate the effects of recombinant human growth hormone (rhGH) on the morphology and function of the left cardiac ventricle in young rats with dilated cardiomyopathy (DCM), and to evaluate the efficacy and safety of rhGH in the treatment of DCM. Methods Sixty male Sprague-Dawley rats were randomly and equally assigned to control group, DCM group, and rhGH group. Furazolidone (0.25 mg/g) was given by gavage for 12 weeks to prepare the DCM model. Rats in the rhGH group received an intraperitoneal injection of rhGH (0.15 U/kg) once per day for 12 weeks, while rats in the DCM group received an equal volume of normal saline instead. Rats in the control group did not receive any treatment. Cardiac indices, serum biochemical parameters, hemodynamic indices, cardiac histopathological changes, and levels of myocardial collagen fibrils in each group were determined using Doppler echocardiography, enzyme-linked immunosorbent assay, multi-channel physiological recorder, light and electron microscopy, and picrosirius red staining plus polarization microscopy, respectively. Results Compared with the control group, rats in the DCM group had significantly increased cardiac chamber size, significantly reduced ventricular wall thickness, and significantly decreased fractional shortening (FS) and ejection fraction (EF) (P<0.05). Rats in the rhGH group had significantly improved cardiac chamber size, ventricular wall thickness, FS, and EF compared with the DCM group (P<0.05). Those indices in the rhGH group were similar to those in the control group (P>0.05). There were significant differences in serum biochemical parameters and hemodynamic indices between the DCM and control groups (P<0.05). Compared with the DCM group, the rhGH group had significantly improved serum biochemical parameters and hemodynamic indices (P<0.05). Those indices in the rhGH group were similar to those in the control group (P>0.05), except for the levels of insulin-like growth factor-1 and insulin-like growth factor-binding protein-3. The DCM group had a significantly higher collagen type I/collagen type III (Col I/Col III) ratio in the myocardium than the control group (P<0.05), and there was no significant difference in the Col I/Col III ratio between the control and rhGH groups (P>0.05). Conclusions rhGH plays a certain role in improvement in the morphology and function of the left cardiac ventricle in young rats with DCM.
关键词
扩张型心肌病 /
生长激素 /
心脏功能 /
血流动力 /
组织病理 /
大鼠
Key words
Dilated cardiomyopathy /
Growth hormone /
Cardiac function /
Hemodynamics /
Histopathology /
Rats
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 杨作成. 小儿扩张型心肌病的诊治[J]. 中华临床医师杂志, 2011, 5(23): 6868-6870.
[2] 蔡小芳, 麦根荣, 徐之良. 小儿扩张型心肌病与病毒性心肌炎的临床研究[J]. 中国当代儿科杂志, 2004, 6(4): 325-327.
[3] Vijayakumar A, Novosyadlyy R, Wu Y, et al. Biological effects of growth hormone on carbohydrate and lipid metabolism[J]. Growth Horm IGF Res, 2010, 20(1): 1-7.
[4] Rasmussen MH. Obesity, growth hormone and weight loss[J]. Mol Cell Endocrinol, 2010, 316(2): 147-153.
[5] Kanashiro-Takeuchi RM, Tziomalos K, Takeuchi LM, et al. Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction[J]. Proc Natl Acad Sci U S A, 2010, 107(6): 2604-2609.
[6] 强欢, 付蓉, 潘凯丽, 等. 不同剂量呋喃唑酮诱导SD大鼠扩张型心肌病模型的实验研究[J]. 现代生物医学进展, 2013, 13(10): 1829-1835.
[7] 强欢, 潘凯丽, 成胜权. 扩张型心肌病动物模型建立的实验研究进展[J]. 医学综述, 2011, 17(19): 2890-2892.
[8] Ohno N, Fedak PW, Weisel RD, et al. Cell transplantation in non-ischemic dilated cardiomyo-pathy: a novel biological approach for ventricular restoration[J]. Jpn J Thorac Cardiovasc Surg, 2002, 50(11): 457-460.
[9] 李彦红, 王风芝. 重组人生长激素和骨髓间质干细胞移植联合治疗阿霉素性心肌病心力衰竭的实验[J]. 中华心血管病杂志, 2008, 36(9): 794-798.
[10] Osterziel KJ, Ranke MB, Strohm O, et al. The somatotrophic system in patients with dilated cardiomyopthy:relation of insulin-like growth factor-1 and its alterations during growth hormone therapy to cardiac function[J]. Clin Endocri, 2000, 53(1): 61-68.
[11] Dreifuss P. Dilated cardiomyopathy and growth hormone[J]. Z Kardiol, 2002, 91 (12): 973-977.
[12] Perrot A, Ranke MB, Dietz R, et al. Growth hormone treatment in dilated cardiomyopathy[J]. J Cardiac Surg, 2001, 16(2): 127-131.
[13] Adamopoulos S, Parissis JT, Georgiadis M, et al. Growth hormone administration reduces circulating proinflammatory cytokines and soluble fas/souble fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy[J]. Am Heart J, 2002, 144(2): 359-364.
[14] Jose VJ, Zechariah TU, George P, et al. Growth hormone therapy in patients with dilated cardiomyopathy: preliminary observations of a pilot study[J]. Indian Heart J, 1999, 51(2): 183-185.
[15] 牛云枫, 程文俊. 生长激素治疗扩张性心肌病前后心电图及激素水平变化[J].实用心电学杂志, 2010, 3(19): 166-168.
[16] Wu Y, Tobias AH, Bell K, et al. Cellular and molecular mechanisms of systolic and diastolic dysfunction in an avian model of dilated cardiomyopathy[J]. J Mol Cell Cardiol, 2004, 15(37): 111-119.
[17] Marin-Garcia J, Goldenthal MJ, Ananthakrishnan R, et al. The complete sequence of mtDNA genes in idiopathic dilated cardiomyopathy shows novel missense and tRNA mutations[J]. J Card Fail, 2000, 6(4): 321-329.
[18] 曹蘅, 蔚有权. 大鼠体内IGF-I水平改变与心肌梗死的关系[J]. 放射免疫学杂志, 2006, 19(5): 355-358.
[19] Borgarelli M, Tarducci A, Tidholm A, et al. Canine idiopathic dilated cardiomyopathy. Part II: pathophysiology and therapy[J]. Vet J, 2001, 162(3): 182-195.
[20] Morrisey EE. Rewind to recover: dedifferentiation after cardiac injury[J]. Cell Stem Cell, 2011, 4(9): 387-389.
[21] 裴汉军, 吴永健, 惠汝太, 等. 阿托伐他汀干预对糖尿病心肌梗死后大鼠左室重构和心功能的影响[J]. 中国分子心脏病学杂志, 2010, 10(1): 23-26.
[22] Sukumaran V, Watanabe K, Veeraveedu PT, et al. Beneficial effects of olmesartan,an angiotensin II receptor type 1 antagonist, in rats with dilated cardiomyopathy[J]. Exp Biol Med, 2010, 235(11): 1338-1346.
[23] Patel R, Nagueh SF, Tsybouleva N, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertohic cardiomypathy[J]. Circulation, 2001, 104(3): 317-324.
[24] Li TS, Takahashi M, Suzuki R, et al. Pravastatin improves remodeling and cardiac function after myocardial infarction by an antiinilammatory mechanism rather than by the induction of angiogenesis[J]. Ann Thorac Surg, 2006, 81(6): 2217-2225.
[25] Martin J, Denver R, Bailey, et al. In vitro inhibitory effects of atorvastatin on cardiac fibmblasts:implications for ventrieular remodeling[J]. Clin Exp Pharnuwol Physiol, 2005, 32(9): 697-701.
基金
金赛儿科中青年内分泌医师科研基金(21460#);陕西省科技社会发展攻关项目(2011K14-01-07)。
PDF(2809 KB)
